Bli medlem
Bli medlem

Du är här


Oncos Therapeutics: Oncos Therapeutics Demonstrates Systemic, Tumor-specific Immune Response by Local Administration of its Lead Product ONCOS-102

-- Phase I Study of ONCOS-102 in Late-stage Refractory Cancer Patients
Successfully Completed and Presented at CIMT Annual Meeting --

Mainz, Germany 8th May 2014 - Oncos Therapeutics, Ltd., a clinical
stage biotechnology company specializing in the development of
targeted cancer immunotherapeutics, presented Phase 1 clinical data
demonstrating that local administration of its lead compound,
ONCOS-102, is able to induce a systemic, tumor-specific immune
response in late-stage cancer patients. The data were presented in
two separate podium presentations on May 7th and 8th at the Annual
Meeting of the Association for Cancer Immunotherapy (CIMT) in Mainz,

In the single center Phase I study conducted at Docrates Cancer Center
in Helsinki, Finland, a total of 12 patients with advanced solid
tumors of different types were treated with up to nine intra-tumoral
injections at three different dose levels of ONCOS-102 - a modified,
tumor-targeted, human adenovirus armed with a potent
immune-stimulating transgene, GM-CSF. The treatment displayed an
excellent safety profile and the study confirmed the dose level for a
forthcoming Phase II clinical trial. Four out of ten evaluable
patients (40%) had stable disease (SD) as defined by Response
Evaluation Criteria In Solid Tumors (RECIST) evaluation three months
after starting ONCOS-102 treatment.

"Demonstrating the induction of tumor-targeted immune responses in
late stage cancer patients is a significant achievement in cancer
immunotherapy, even though the number of study subjects was limited
in this trial." said Magnus Jaderberg, M.D., Chief Medical Officer of

During the trial, a number of biological samples were collected prior
to and after ONCOS-102 treatment to evaluate the biological activity
of the therapy. Sample analysis showed that the treatment triggered
an immediate innate immune response as measured by:

- a temporary increase in pro-inflammatory cytokines; and
- infiltration of innate immune cells into the tumor area.
These responses were seen in both blood and tumor biopsies. Also an
infiltration of CD8+ T cells of cytotoxic phenotype was seen in
post-treatment biopsies. Analysis of the antigen specificity of
cytotoxic T-cells in peripheral blood prior to and after treatment
with ONCOS-102 showed that the therapy induced a tumor-specific
immunity in patients with advanced solid tumors.

"These results clearly demonstrate the potential of our immunotherapy
platform", said Frans Wuite, M.D., President and Chief Executive
Officer of Oncos. "We now intend to move our lead compound forward to
Phase II in selected indications in combination with other
anti-cancer treatments, including immune checkpoint inhibitors."

About ONCOS-102
ONCOS-102 (Ad5/3-D24-GMCSF) is a modified, tumor-targeted human
adenovirus capable of local delivery of a potent immune-stimulating
transgene, granulocyte-macrophage colony-stimulating factor to the
tumor microenvironment. In addition to this Phase I study, the safety
of ONCOS-102 has been demonstrated in over 100 patients with
refractory cancers who received treatment with ONCOS-102 under
compassionate use circumstances.

About Oncos Therapeutics
Oncos Therapeutics Ltd is a privately funded clinical-stage
biotechnology company focused on the development and
commercialization of targeted cancer immunotherapy products that
induce a tailored immune response targeted against each patient's
unique cancer cells. In addition to its lead product, ONCOS-102,
Oncos has generated a pipeline of clinical candidates using its
adenovirus-based cancer immunotherapeutics platform. The company's
lead investor is HealthCap, one of the largest specialized providers
of venture capital within life sciences in Europe. Oncos, founded in
2009, is headquartered in Helsinki, Finland and has an office in
Switzerland. For more information about Oncos, please visit

Contact Information
Dr. Frans Wuite, President and CEO
Oncos Therapeutics Ltd.
Direct: +41 79 340 8218

Dr. Anca Alexandru
MacDougall Biomedical Communications
Direct: +49163 613 3359


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.